Merck May Eventually Own Up to 20 Percent of Genaissance in Pharmacogenomics Agreement | GenomeWeb

This article has been updated from a previous version.

NEW YORK, Sept. 24 (GenomeWeb News) - Merck may eventually own up to 19.9 percent of Genaissance as a  result of a license agreement between the companies in which Genaissance will use its haplotyping technology to develop a Merck antidepressant, said Genaissance CEO Kevin Rakin yesterday in a conference call. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.